Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMV102 in Relapsed/Refractory Multiple Myeloma
NCT07493135Phase 1Recruiting
- Sponsor
- Immunofoco
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iMagic Injection in multiple myeloma (MM), sponsored by Immunofoco. Primary endpoint: Safety of IMV102 injection at 24 months. Started Apr 2026; status: recruiting.
02
Drugs
iMagic Injection
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07493135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493135.